Preferred Label : Anti-PD1/IL-15 Fusion Protein SAR445877;
NCIt synonyms : Anti-PD1 Antibody-IL15 Mutant Fusion Protein SAR445877; mut-1N-IL-15/38B2;
NCIt definition : A fusion protein composed of an antibody moiety targeting the negative immunoregulatory
human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to
a mutein of the immunostimulatory cytokine interleukin-15 (IL-15), with potential
immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon
administration of anti-PD1/IL-15 fusion protein SAR445877, the PD-1 targeting moiety
specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways.
This may restore immune function through the activation of T-cells and T-cell-mediated
immune responses against tumor cells. The IL-15 mutein moiety binds to the IL-15 receptor
and activates IL-15-mediated signaling. This stimulates the proliferation of natural
killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the
tumor microenvironment (TME), and induces an anti-tumor immune response. This may
increase tumor cell killing and decrease tumor cell proliferation. PD-1, a transmembrane
protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as
an immune checkpoint that negatively regulates T-cell activation and effector function
when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of
differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion
from host immunity. IL-15 regulates CD8 T and NK cell development, activation and
proliferation. The IL-15 mutein form lowers the systemic toxicity of IL-15.;
Molecule name : SAR-445877; KD-050; SAR 445877; KD 050;
NCI Metathesaurus CUI : CL1912848;
Origin ID : C192821;
UMLS CUI : C5785442;
Semantic type(s)
- concept_is_in_subset
- has_target
